Related Experiment Video
Updated: Aug 4, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable devices for management of chronic heart failure: defibrillators and biventricular pacing therapy
1Department of Medicine, St John Hospital and Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 48236, USA. luis.pires@stjohn.org
Insights
Device therapy, including implantable cardioverter-defibrillators and cardiac resynchronization therapy, offers significant benefits for managing chronic heart failure patients, improving survival and quality of life.
Area of Science:
- Cardiology
- Medical Devices
Background:
- Chronic heart failure (CHF) is a growing epidemic with high morbidity and mortality.
- Pharmacologic therapy improves survival but does not fully address CHF challenges.
Purpose of the Study:
- To review recent advancements in non-pharmacologic, device-based treatments for chronic heart failure.
- To highlight the role of implantable cardioverter-defibrillators and cardiac resynchronization therapy in CHF management.
Main Methods:
- Review of recent clinical trials and data on device-based therapies for CHF.
- Analysis of outcomes for implantable cardioverter-defibrillator (ICD) and biventricular pacing (cardiac resynchronization therapy - CRT).
Main Results:
- ICD therapy significantly reduces mortality in mild to moderate heart failure by preventing sudden arrhythmic death.
- CRT improves symptoms, quality of life, exercise tolerance, and left ventricular function in advanced heart failure patients with specific criteria (LVEF ≤ 35%, QRS > 120 ms).
- Approximately 30% of patients do not respond to CRT; ongoing studies aim to identify responders and explore CRT in patients with normal QRS duration.
Conclusions:
- Device therapy (ICD and CRT) is an integral, adjunctive component of chronic heart failure management alongside optimal medical therapy.
- The choice of device depends on individual patient characteristics and clinical presentation.
Purpose Of Review:
With chronic heart failure already an epidemic in the USA, its prevalence is expected to rise significantly in the future. Despite improved survival with pharmacologic therapy, the morbidity and mortality of patients with heart failure remain high. The purpose of this review, therefore, is to present recent data on the non-pharmacologic, device-based treatment of patients with chronic heart failure.
Recent Findings:
The implantable cardioverter-defibrillator has become standard treatment for the prevention of sudden, arrhythmic death. Recent well-designed clinical trials have led to device-based therapy as an important component in the management of patients with systolic left ventricular dysfunction (resulting from both ischemic and non-ischemic etiologies) and symptomatic chronic heart failure. Implantable cardioverter-defibrillator therapy alone (without biventricular pacing) results in a significant reduction in the overall mortality of patients with mild and moderate heart failure. Biventricular pacing (or cardiac resynchronization therapy) with or without a back-up implantable cardioverter-defibrillator, compared with optimal pharmacologic therapy, improves symptoms, quality of life, exercise tolerance, left ventricular function, and the survival of patients with advanced heart failure, a left ventricular ejection fraction of 35% or less, and intraventricular conduction delays (QRS > 120 ms), although up to approximately 30% of patients do not respond to cardiac resynchronization therapy. Ongoing and planned studies should clarify which patients are most likely to respond to cardiac resynchronization therapy and elucidate its role in those with a normal (< 120 ms) QRS (approximately 70% of patients with heart failure).
Summary:
Device therapy (implantable cardioverter-defibrillator and cardiac resynchronization therapy) should be considered an integral, but adjunctive, part of the management of patients with chronic heart failure who are receiving appropriate medical therapy. The type of device used will depend on the individual patient's clinical characteristics.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

